Several companies have reported their fourth-quarter earnings, with mixed results. ChromaDex (CDXC) reported a GAAP EPS of $0.09, beating estimates by $0.02, and sales of $29.125 million, exceeding the $26.733 million estimate. Credo Technology Group (CRDO) posted an adjusted EPS of $0.25, surpassing the $0.18 estimate, with sales of $135 million, beating the $120.061 million estimate. The company also provided guidance for Q4 revenue between $155 million and $165 million, higher than the FactSet analyst consensus of $137 million. Crexendo (CXDO) achieved an adjusted EPS of $0.06, beating the $0.05 estimate, and sales of $16.24 million, exceeding the $15.64 million estimate. Other companies, including Evolus (EOLS), CryoPort (CYRX), and Nevro (NVRO), reported losses that missed analyst expectations, while EyePoint Pharmaceuticals (EYPT) also fell short of EPS estimates but exceeded sales expectations. Turning Point Brands (TPB) announced an adjusted EPS of $0.98, beating the $0.91 estimate, although sales of $93.67 million missed the $95.07 million estimate. Overall, the earnings reports reflect a diverse performance across various sectors.